In:
Journal of Gastroenterology and Hepatology, Wiley, Vol. 32, No. 12 ( 2017-12), p. 1943-1948
Abstract:
DA‐9701, a newly developed prokinetic agent formulated with Pharbitis Semen and Corydalis Tuber, has been shown to effectively treat functional dyspepsia. Recently, it has also been suspected to improve gastrointestinal motor function. The aims of this study were to assess the effect of DA‐9701 on colonic transit time (CTT) and symptoms of functional constipation. Methods Thirty‐three patients with functional constipation based on the Rome III criteria were prospectively enrolled. The patients received 30‐mg DA‐9701 three times a day for 24 days. CTT was estimated initially and at the end of treatment. Symptoms such as spontaneous bowel movements, straining, stool form, feeling of incomplete emptying and anorectal blockage, abdominal discomfort and pain, overall defecation satisfaction, and incidence of adverse events were also analyzed. Results Twenty‐seven patients completed the study. DA‐9701 was associated with a significantly reduced CTT from 34.9 ± 17.6 to 23.7 ± 19.1 h ( P = 0.001). Segmental CTT also significantly decreased after treatment (right CTT: from 16.8 [0.0–28.8] to 6.0 [0.0–25.2] hours, P 〈 0.001; rectosigmoid transit time: from 13.2 [0.0–38.4] to 6.0 [0.0–33.6] hours, P = 0.021). In addition, all constipation‐related subjective symptoms, including spontaneous bowel movement frequency, significantly improved compared with those before treatment. Serious adverse events did not occur. Conclusions DA‐9701 accelerates colonic transit and safely improves symptoms in patients with functional constipation. Therefore, we suggest that this novel agent could help to treat patients with this condition.
Type of Medium:
Online Resource
ISSN:
0815-9319
,
1440-1746
DOI:
10.1111/jgh.2017.32.issue-12
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
2006782-3
